SABS - SAB Biotherapeutics, Inc.
IEX Last Trade
3.66
-0.180 -4.918%
Share volume: 57,960
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$3.84
-0.18
-0.05%
View ratios
| Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2023-05-15 | 2023-08-21 | 2023-11-13 | 2024-03-29 | 2024-05-20 | 2024-08-08 | 2024-11-06 | |
| Assets | ||||||||
| Total Assets | 42.672 M | 35.443 M | 28.336 M | 83.941 M | 71.371 M | 61.892 M | 53.797 M | |
| Current Assets | 15.032 M | 9.006 M | 3.128 M | 58.907 M | 46.951 M | 39.580 M | 32.537 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.209 M | 867.604 K | 702.231 K | 2.341 M | 2.701 M | 224.924 K | 97.047 K | |
| Short Term Investments | 1.209 M | 867.604 K | 702.231 K | 2.341 M | 2.701 M | 20.084 M | 21.229 M | |
| Total Receivables | 763.123 K | 364.117 K | 0.000 | 0.000 | 193.232 K | 0.000 | 0.000 | |
| Current Cash | 13.060 M | 7.774 M | 2.425 M | 56.566 M | 44.057 M | 17.242 M | 9.171 M | |
| Total Non-current Assets | 27.640 M | 26.436 M | 25.209 M | 25.034 M | 24.420 M | 0.000 | 0.000 | |
| Property Plant Equipment | 22.374 M | 21.528 M | 20.622 M | 19.737 M | 17.903 M | 16.921 M | 16.077 M | |
| Other Assets | 5.266 M | 4.909 M | 4.587 M | 5.298 M | 5.282 M | 5.390 M | 5.184 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 42.672 M | 35.443 M | 28.336 M | 83.941 M | 71.371 M | 61.892 M | 53.797 M | |
| Total liabilities | 18.269 M | 15.726 M | 13.080 M | 26.642 M | 18.549 M | 15.772 M | 16.895 M | |
| Total current liabilities | 13.666 M | 11.011 M | 9.211 M | 10.813 M | 8.305 M | 7.552 M | 8.816 M | |
| Accounts Payable | 1.445 M | 1.404 M | 1.083 M | 945.927 K | 1.240 M | 6.226 M | 8.177 M | |
| Other liabilities | 238.344 K | 595.860 K | 417.102 K | 11.774 M | 6.306 M | 8.220 M | 8.078 M | |
| Current long term debt | 1.095 M | 784.880 K | 1.200 M | 1.853 M | 1.513 M | 0.000 | 0.000 | |
| Long term debt | 4.365 M | 4.119 M | 3.452 M | 4.054 M | 3.938 M | 0.000 | 0.000 | |
| Other liabilities | 238.344 K | 595.860 K | 417.102 K | 11.774 M | 6.306 M | 8.220 M | 8.078 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 24.403 M | 19.716 M | 15.256 M | 57.299 M | 52.822 M | 46.120 M | 36.903 M | |
| Common stock | 50.397 M | 50.421 M | 52.406 M | 6.764 M | 9.242 M | 154.097 M | 155.146 M | |
| Retained earnings | -55.224 M | -62.104 M | -67.207 M | -90.064 M | -95.089 M | -102.425 M | -112.774 M |